AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2019 - ResearchAndMarkets.com

April 1, 2019

DUBLIN--(BUSINESS WIRE)--Apr 1, 2019--The “Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Primary Progressive Multiple Sclerosis (PPMS) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Primary Progressive Multiple Sclerosis (PPMS)
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Primary Progressive Multiple Sclerosis (PPMS)
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Progressive Multiple Sclerosis (PPMS)
  • The report also covers the dormant and discontinued pipeline projects related to Primary Progressive Multiple Sclerosis (PPMS)

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Primary Progressive Multiple Sclerosis (PPMS) to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Primary Progressive Multiple Sclerosis (PPMS) therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Primary Progressive Multiple Sclerosis (PPMS) Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix
  • Kyorin Pharmaceutical Co.
  • MedDay S.A.
  • Santhera Pharmaceuticals Holding AG
  • Teva Pharmaceutical Industries Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d2kn8p/primary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190401005789/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/01/2019 02:36 PM/DISC: 04/01/2019 02:36 PM

http://www.businesswire.com/news/home/20190401005789/en